Abstract:Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of aberrant cells. Thus, RCD pathways represented by apoptosis have increased in importance as a target for the development of cancer medications in recent years. However, because tumor cells show avoidance to apoptosis, which causes treatment resistance and recurrence, numerous studies have been devoted to alternative cancer cell mortality processes, namely necroptosis, pyroptosis, ferroptosis, and cuproptosis; these RCD modalities have been extensively studied and shown to be crucial to cancer therapy effectiveness. Furthermore, evidence suggests that tumor cells undergoing regulated death may alter the immunogenicity of the tumor microenvironment (TME) to some extent, rendering it more suitable for inhibiting cancer progression and metastasis. In addition, other types of cells and components in the TME undergo the abovementioned forms of death and induce immune attacks on tumor cells, resulting in enhanced antitumor responses. Hence, this review discusses the molecular processes and features of necroptosis, pyroptosis, ferroptosis, and cuproptosis and the effects of these novel RCD modalities on tumor cell proliferation and cancer metastasis. Importantly, it introduces the complex effects of novel forms of tumor cell death on the TME and the regulated death of other cells in the TME that affect tumor biology. It also summarizes the potential agents and nanoparticles that induce or inhibit novel RCD pathways and their therapeutic effects on cancer based on evidence from in vivo and in vitro studies and reports clinical trials in which RCD inducers have been evaluated as treatments for cancer patients. Lastly, we also summarized the impact of modulating the RCD processes on cancer drug resistance and the advantages of adding RCD modulators to cancer treatment over conventional treatments.

Regulated Cell Death in Endometriosis

Apoptosis and Endometriosis

Elevated Immunoreactivity of RANTES and CCR1 Correlate with the Severity of Stages and Dysmenorrhea in Women with Deep Infiltrating Endometriosis.

Hypoxia Activates the Unfolded Protein Response Signaling Network: an Adaptive Mechanism for Endometriosis

Regulated cell death (RCD) in cancer: key pathways and targeted therapies

Endometriosis: Cell Death and Cell Signaling Machinery

Regulated Cell Death in Cancer: from Pathogenesis to Treatment

The regulated cell death at the maternal-fetal interface: beneficial or detrimental?

Regulated cell death pathways in cardiomyopathy

Regulated cell death: discovery, features and implications for neurodegenerative diseases

The molecular machinery of regulated cell death

LncRNAs and regulated cell death in tumor cells

Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential

Regulated Cell Death in Musculoskeletal Development, Homeostasis, and Diseases

Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research

Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy

Epigenetic Regulation of Diverse Regulated Cell Death Modalities in Cardiovascular Disease:Insights into Necroptosis, Pyroptosis, Ferroptosis, and Cuproptosis

Role of Pyroptosis in Endometrial Cancer and Its Therapeutic Regulation

Regulated Cell Death in Urinary Malignancies

Emerging mechanisms of lipid peroxidation in regulated cell death and its physiological implications

Gene Expression Regulation and the Signal Transduction of Programmed Cell Death